For Academic pricing please login or contact us at discoverysciences@invitrogen.com.


GeneBLAzer® EDG3-Gα15-NFAT-bla HEK293T cells contain the human Endothelial Differentiation Receptor 3 (EDG3) stably integrated into the GeneBLAzer® EDG3-Gα15-NFAT-bla HEK293T cell line. GeneBLAzer® Gα15-NFAT-bla HEK293T cells (Cat. no. K1539) contain a beta-lactamase reporter gene under control of the Nuclear Factor of Activated T-cells (NFAT) response element and the Promiscuous G protein, Gα15.

The GeneBLAzer® EDG3-Gα15-NFAT-bla HEK293T cells are functionally validated for Z' and EC50 concentrations of S1P. In addition, GeneBLAzer® EDG3-Gα15-NFAT-bla HEK293T cells have been tested for assay performance under variable conditions. These data are found in the Validation & Assay Performance Summary.

EDG-3⁄S1P-3(Sphingosine-1-Phosphate-3) is a Gq⁄Gi⁄Go⁄Gα13⁄Gα12 coupled GPCR. EDG-3 has been shown to be responsible for bradycardia that has been induced in clinical trials as a side effect of the immunosuppressive drug FTY720 that targets EDG-1. EDG-3 has also been shown to induce vasodilation in response to sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF). The EDG-3 Receptor has also been shown to play a cooperative or redundant role in angiogenesis with EDG-1.